{
    "clinical_study": {
        "@rank": "144507", 
        "arm_group": {
            "arm_group_label": "SPI-1620 & Docetaxel", 
            "arm_group_type": "Experimental", 
            "description": "SPI-1620 11 \u03bcg/m2 will be given intravenously over 1 minute.\nDocetaxel 75 mg/m2 infusion will be administered per standard of care 10 (\u00b12) minutes after SPI-1620."
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to determine the effectiveness of SPI-1620 in\n      combination with docetaxel in patients with advanced biliary cancer."
        }, 
        "brief_title": "Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Biliary Cancer", 
        "condition_browse": {
            "mesh_term": "Biliary Tract Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed biliary tract or  gallbladder cancer that have relapsed or\n             are refractory after one prior gemcitabine-based chemotherapy regimen for advanced\n             biliary cancer\n\n          -  Evaluable disease\n\n          -  ECOG PS \u2264 2\n\n          -  Adequate bone marrow, liver and renal function\n\n        Exclusion Criteria:\n\n          -  Treatment with more than one prior chemotherapy regimen\n\n          -  Known, uncontrolled CNS metastases\n\n          -  Baseline peripheral neuropathy \u2265 grade 2.\n\n          -  Significant circulatory disorders in the past 6 months\n\n          -  Concomitant use of phosphodiesterase inhibitors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773785", 
            "org_study_id": "SPI-1620-12-202"
        }, 
        "intervention": {
            "arm_group_label": "SPI-1620 & Docetaxel", 
            "description": "Patients will receive 11 \u03bcg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (\u00b12 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.", 
            "intervention_name": "SPI-1620 & Docetaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "k.mertz-rivera@med.miami.edu", 
                    "last_name": "Kamara Mertz-Rivera", 
                    "phone": "305-243-0864"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami Hospitals & Clinics/ Sylvester Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Caio Rocha Lima, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Richard Kim, MD", 
                    "phone": "813-745-3537"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Richard Kim, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Melissa Haley"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Manik Amin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jitendra Gandhi, MD", 
                    "phone": "423-622-2337"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37421"
                    }, 
                    "name": "Associates in Oncology and Hematology"
                }, 
                "investigator": {
                    "last_name": "Jitendra Gandhi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cinman@WESTCLINIC.com", 
                    "last_name": "Cindy Inman", 
                    "phone": "901-683-0055"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "The West Clinic"
                }, 
                "investigator": {
                    "last_name": "David Portnoy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lmwhite@seattlecca.org", 
                    "last_name": "Lisa White", 
                    "phone": "206-288-7350"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }, 
                "investigator": {
                    "last_name": "Elena Chiorean, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer", 
        "overall_contact": {
            "email": "angie.schinkel@sppirx.com", 
            "last_name": "Angie Schinkel", 
            "phone": "949-743-9257"
        }, 
        "overall_official": {
            "affiliation": "Spectrum Pharmaceuticals, Inc", 
            "last_name": "Mi Rim Choi, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773785"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Periodic physical examinations with vital sign monitoring, safety laboratories and monitoring of adverse events will be performed", 
                "measure": "Safety of SPI-1620 when administered in combination with docetaxel", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}